High CDK9 expression level correlates with poor prognosis and drug resistance in several cancer types including with breast cancer, lung cancer, prostate cancer, endometrial cancer, melanoma, osteosarcoma, myeloid leukemia, and soft tissue sarcoma [51]. This evidence concerns the gene CDK9 and lung carcinoma.